In addition, the novel lipopeptides, especially LP2-2, enhanced systemic and mucosal antibody response when intranasally administrated with rRBD, suggesting that lipopeptides may serve as a potent adjuvant for COVID-19 vaccine. This evidence concerns the gene RPLP2 and COVID-19.